Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis

References

• Sokolov RA, Rachmaninoff N, Kaine HD. Allergic granulomatosis. Am J Med. 1962;32:131–141.
   PubMed Web of Science ®Google Scholar
• Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27:277–301.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of Systemic Vasculitides. Arthritis Rheum. 1994;37:187–192.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. Revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013 2012;65:1–11.
   PubMed Web of Science ®Google Scholar
• Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg–strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26:545–553.
   PubMed Web of Science ®Google Scholar
• McGeoch L, Twilt M, Famorca L, et al. CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol. 2016;43:97–120.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65:270–281.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–strauss). Ann Rheum Dis. 2016;75:396–401.
   PubMed Web of Science ®Google Scholar
• Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72:1011–1017.
   PubMed Web of Science ®Google Scholar
• Tatsis E. Interferon-α treatment of four patients with the churg-strauss syndrome. Ann Intern Med. 1998;129:370.
   PubMed Web of Science ®Google Scholar
• Navarro-Mendoza EP, Tobón GJ. Eosinophilic granulomatosis with polyangiitis: newer therapies. Curr Rheumatol Rep. 2018;20. DOI:10.1007/s11926-018-0736-2.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921–1932.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in churg-strauss syndrome. Ann N Y Acad Sci. 2005;1051:121–131.
   PubMed Web of Science ®Google Scholar
• Jakiela B, Szczeklik W, Plutecka H, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg–strauss syndrome patients. Rheumatology. 2012;51:1887–1893.
   PubMed Web of Science ®Google Scholar
• Schnabel A, Csernok E, Braun J, et al. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax. 1999;54:771–778.
   PubMed Web of Science ®Google Scholar
• Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol. 2014;10:474–483.
   PubMed Web of Science ®Google Scholar
• Eng SS, DeFelice ML. The role and immunobiology of eosinophils in the respiratory system: a comprehensive review. Clin Rev Allergy Immunol. 2016;50:140–158.
   PubMed Web of Science ®Google Scholar
• Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom. Arthritis Rheum. 2000;43:414–419.
   PubMed Web of Science ®Google Scholar
• Martin RM, Wilton LV, Mann RD. Prevalence of Churg–strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf. 1999;8:179–189.
   PubMed Web of Science ®Google Scholar
• Gonzalez‐Gay MA, Garcia‐Porrua C, Guerrero J, et al. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Care Res. 2003;49:388–393.
   Web of Science ®Google Scholar
• Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: A capture–recapture estimate. Arthritis Care Res. 2004;51:92–99.
   Web of Science ®Google Scholar
• Sada K-E, Amano K, Uehara R, et al. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol. 2014;24:640–644.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Jacobsson LTH, Mahr AD, et al. Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg Strauss syndrome within a defined population in southern Sweden. Rheumatology. 2007;46:1329–1337.
   PubMed Web of Science ®Google Scholar
• Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63:65–81.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Guilpain P, Guillevin L. Churg–strauss syndrome. Curr Opin Rheumatol. 2007;19:25–32.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Casazza I, Grasselli C, et al. Churg–strauss syndrome. Kidney Int. 2009;76:1006–1011.
   PubMed Web of Science ®Google Scholar
• Guillevin LMD, Cohen PMD, Gayraud MMD, et al. Churg-strauss syndrome clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78:26–37.
   PubMed Web of Science ®Google Scholar
• Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284–290.
   PubMed Web of Science ®Google Scholar
• Sinico RA, Toma LD, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2926–2935.
   PubMed Web of Science ®Google Scholar
• Reid AJ, Harrison BD, Watts RA, et al. Churg-Strauss syndrome in a district hospital. QJM Mon J Assoc Physicians. 1998;91:219–229.
   PubMedGoogle Scholar
• Solans R, Bosch JA, Pérez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatol Oxf Engl. 2001;40:763–771.
   PubMed Web of Science ®Google Scholar
• Healy B, Bibby S, Steele R, et al. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol. 2013;131:571–576.e6.
   PubMed Web of Science ®Google Scholar
• Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the churg–strauss syndrome. Ann Intern Med. 2005;143:632.
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Smythe H, Lewtas J, et al. Outcome of polyarteritis nodosa and churg-strauss syndrome. Arthritis Rheum. 1994;37:1798–1803.
   PubMed Web of Science ®Google Scholar
• Chumbley LC, Harrison EG, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc. 1977;52:477–484.
   PubMed Web of Science ®Google Scholar
• Della Rossa A, Baldini C, Tavoni A, et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatol Oxf Engl. 2002;41:1286–1294.
   PubMed Web of Science ®Google Scholar
• Gaskin G, Clutterbuck EJ, Pusey CD. Renal disease in the Churg-Strauss syndrome. Diagnosis, management and outcome. Contrib Nephrol. 1991;94:58–65.
   PubMedGoogle Scholar
• Haas C, Le Jeunne C, Choubrac P, et al. Churg-Strauss syndrome. Retrospective study of 20 cases. Bull Acad Natl Med. 2001;185: 1113–1130. discussion 1130-1133.
   PubMed Web of Science ®Google Scholar
• Oh M-J, Lee J-Y, Kwon N-H, et al. Churg-Strauss Syndrome: the Clinical Features and Long-term Follow-up of 17 Patients. J Korean Med Sci. 2006;21:265–271.
   PubMed Web of Science ®Google Scholar
• Samson M, Puéchal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg–strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–69.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg–strauss): state of the art. Allergy. 2013;68:261–273.
   PubMed Web of Science ®Google Scholar
• Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol. 2016;3:122–133.
   PubMed Web of Science ®Google Scholar
• Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev. 2017;16:1–9.
   PubMed Web of Science ®Google Scholar
• Sokolowska BM, Szczeklik WK, Wludarczyk AA, et al. ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center. Clin Exp Rheumatol. 2014;32:S41–47.
   PubMed Web of Science ®Google Scholar
• Grayson PC, Monach PA, Pagnoux C, et al. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology. 2015;54:1351–1359.
   PubMed Web of Science ®Google Scholar
• Ramentol-Sintas M, Martínez-Valle F, Solans-Laqué R. Churg–strauss Syndrome: an evolving paradigm. Autoimmun Rev. 2012;12:235–240.
   PubMed Web of Science ®Google Scholar
• Zwerina J, Axmann R, Jatzwauk M, et al. Pathogenesis of Churg–strauss syndrome: recent insights: mini Review. Autoimmunity. 2009;42:376–379.
   PubMed Web of Science ®Google Scholar
• Lane SE, Watts RA, Bentham G, et al. Are environmental factors important in primary systemic vasculitis?: A case–control study. Arthritis Rheum. 2003;48:814–823.
   PubMed Web of Science ®Google Scholar
• Greco A, Rizzo MI, De Virgilio A, et al. Churg–strauss syndrome. Autoimmun Rev. 2015;14:341–348.
   PubMed Web of Science ®Google Scholar
• Celebi Sozener Z, Gorgulu B, Mungan D, et al. Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases. World Allergy Organ J. 2018;11. DOI:10.1186/s40413-018-0217-0.
   PubMed Web of Science ®Google Scholar
• Detoraki A, Di Capua L, Varricchi G, et al. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma. 2016;53:201–206.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Guilpain P, Hauser T, et al. Churg-Strauss Syndrome and Leukotriene-Modifying Agents. Clin Pulm Med. 2004;11:349.
   Google Scholar
• Bibby S, Healy B, Steele R, et al. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax. 2010;65:132–138.
   PubMed Web of Science ®Google Scholar
• Beasley R, Bibby S, Weatherall M. Leukotriene receptor antagonist therapy and Churg-Strauss syndrome: culprit or innocent bystander? Thorax. 2008;63:847–849.
   PubMed Web of Science ®Google Scholar
• Calapai G, Casciaro M, Miroddi M, et al. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology. 2014;94:60–70.
   PubMed Web of Science ®Google Scholar
• Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008;63:677–682.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Martorana D, Maggiore U, et al. HLA–DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum. 2007;56:3159–3166.
   PubMed Web of Science ®Google Scholar
• Bonatti F, Reina M, Neri TM, et al. Genetic Susceptibility to ANCA-Associated Vasculitis: state of the Art. Front Immunol. 2014;5. DOI:10.3389/fimmu.2014.00577.
   PubMed Web of Science ®Google Scholar
• Coit P, Direskeneli H, Sawalha AH. An update on the role of epigenetics in systemic vasculitis. Curr Opin Rheumatol. 2018;30:4–15.
   PubMed Web of Science ®Google Scholar
• Yang J, Ge H, Poulton CJ, et al. Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Clin Epigenetics. 2016;8. DOI:10.1186/s13148-016-0251-0.
   Web of Science ®Google Scholar
• Jones BE, Yang J, Muthigi A, et al. Gene-Specific DNA methylation changes predict remission in patients with ANCA-associated vasculitis. J Am Soc Nephrol JASN. 2017;28:1175–1187.
   PubMed Web of Science ®Google Scholar
• Alba M, Jennette J, Falk R. Pathogenesis of ANCA-Associated Pulmonary Vasculitis. Semin Respir Crit Care Med. 2018;39:413–424.
   PubMed Web of Science ®Google Scholar
• Xiao H, Hu P, Falk RJ, et al. Overview of the Pathogenesis of ANCA-Associated Vasculitis. Kidney Dis. 2016;1:205–215.
   Google Scholar
• Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol. 2008;20:55–60.
   PubMed Web of Science ®Google Scholar
• Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955–963.
   PubMed Web of Science ®Google Scholar
• Little MA, Smyth L, Salama AD, et al. Experimental Autoimmune Vasculitis. Am J Pathol. 2009;174:1212–1220.
   PubMed Web of Science ®Google Scholar
• Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase–antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol. 2004;93:398–401.
   PubMed Web of Science ®Google Scholar
• Raffray L, Guillevin L. Treatment of Eosinophilic Granulomatosis with Polyangiitis: a review. Drugs. 2018;78:809–821.
   PubMed Web of Science ®Google Scholar
• Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis–a meta-analysis. Rheumatology. 2012;51:100–109.
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Thomas SR, Radford K, et al. Sputum antineutrophil cytoplasmic antibodies in serum antineutrophil cytoplasmic antibody–negative eosinophilic granulomatosis with polyangiitis. Am J Respir Crit Care Med. 2019;199:158–170.
   PubMed Web of Science ®Google Scholar
• Pease JE. Asthma, allergy and chemokines. Curr Drug Targets. 2006;7:3–12.
   PubMed Web of Science ®Google Scholar
• Berkman N, Ohnona S, Chung FK, et al. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol. 2001;24:682–687.
   PubMed Web of Science ®Google Scholar
• Shinkai A, Yoshisue H, Koike M, et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol Baltim Md 1950. 1999;163:1602–1610.
   Google Scholar
• Polzer K, Karonitsch T, Neumann T, et al. Eotaxin-3 is involved in Churg–strauss syndrome – a serum marker closely correlating with disease activity. Rheumatology. 2008;47:804–808.
   PubMed Web of Science ®Google Scholar
• Zwerina J, Bach C, Martorana D, et al. Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatol Oxf Engl. 2011;50:1823–1827.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Eosinophil granule proteins and their role in disease. Curr Opin Hematol. 2001;8:28–33.
   PubMed Web of Science ®Google Scholar
• Kiene M, Csernok E, Müller A, et al. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum. 2001;44:469–473.
   PubMed Web of Science ®Google Scholar
• Terrier B, Bieche I, Maisonobe T, et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood. 2010;116:4523–4531.
   PubMed Web of Science ®Google Scholar
• Khoury P, Zagallo P, Talar‐Williams C, et al. Serum biomarkers are similar in Churg–strauss syndrome and hypereosinophilic syndrome. Allergy. 2012;67:1149–1156.
   PubMed Web of Science ®Google Scholar
• Ralston DR, Marsh CB, Lowe MP, et al. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors. J Clin Invest. 1997;100:1416–1424.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Nair P, Xi Y, et al. Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. Clin Exp Rheumatol. 2019 Jan 14. Epub ahead of print.
   Web of Science ®Google Scholar
• Migita M, Yamaguchi N, Mita S, et al. Characterization of the human IL-5 receptors on eosinophils. Cell Immunol. 1991;133:484–497.
   PubMed Web of Science ®Google Scholar
• Shahabuddin S, Ponath P, Schleimer RP. Migration of eosinophils across endothelial cell monolayers: interactions among IL-5, endothelial-activating cytokines, and C-C Chemokines. J Immunol. 2000;164:3847–3854.
   PubMed Web of Science ®Google Scholar
• Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood. 1989;73:1504–1512.
   PubMed Web of Science ®Google Scholar
• Clutterbuck E, Shields JG, Gordon J, et al. Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur J Immunol. 1987;17:1743–1750.
   PubMed Web of Science ®Google Scholar
• Warren DJ, Moore MA. Synergism among interleukin 1, interleukin 3, and interleukin 5 in the production of eosinophils from primitive hemopoietic stem cells. J Immunol Baltim Md 1950. 1988;140:94–99.
   Google Scholar
• Yamaguchi Y, Suda TO, Suda J, Eguchi MI, Miura Y, Harada NO, Tominaga A, Takatsu K. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med. 1988;167:43–56.
   PubMed Web of Science ®Google Scholar
• Mould AW, Matthaei KI, Young IG, et al. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest. 1997;99:1064–1071.
   PubMed Web of Science ®Google Scholar
• Jakiela B, Szczeklik W, Sokolowska B, et al. Intrinsic pathway of apoptosis in peripheral blood eosinophils of Churg–strauss syndrome. Rheumatology. 2009;48:1202–1207.
   PubMed Web of Science ®Google Scholar
• Schmitt WH, Csernok E, Kobayashi S, et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum. 1998;41:445–452.
   PubMed Web of Science ®Google Scholar
• Tsurikisawa N, Saito H, Tsuburai T, et al. Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol. 2008;122:610–616.
   PubMed Web of Science ®Google Scholar
• Jakiela B, Sanak M, Szczeklik W, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol. 2011;29:S23–34.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Strehl JD, Manger B, et al. IgG4 immune response in Churg–strauss syndrome. Ann Rheum Dis. 2012;71:390–393.
   PubMed Web of Science ®Google Scholar
• Thiel J, Troilo A, Salzer U, et al. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract. 2017;5:1556–1563.
   PubMed Web of Science ®Google Scholar
• Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatol Oxf Engl. 2008;47:1104–1105.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2011;26:2865–2871.
   PubMed Web of Science ®Google Scholar
• Tsurikisawa N, Saito H, Oshikata C, et al. Decreases in the numbers of peripheral blood regulatory T Cells, and Increases in the levels of memory and activated B Cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol. 2013;33:965–976.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European league against rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67:1004–1010.
   PubMed Web of Science ®Google Scholar
• Nguyen Y, Guillevin L. Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). Semin Respir Crit Care Med. 2018;39:471–481.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Seror R, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) Cohort. Medicine (Baltimore). 2011;90:19–27.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Groh M. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Expert Rev Clin Immunol. 2016;12:1059–1067.
   PubMed Web of Science ®Google Scholar
• Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Care Res. 2007;57:686–693.
   Web of Science ®Google Scholar
• Puéchal X, Pagnoux C, Baron G, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (churg-strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors. Arthritis Rheumatol. 2017;69:2175–2186.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Cappelli M, Malcangi G, et al. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. 2004;63:1649–1654.
   PubMed Web of Science ®Google Scholar
• Crickx E, Machelart I, Lazaro E, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French Nationwide Study of Ninety-Two Patients. Arthritis Rheumatol Hoboken NJ. 2016;68:702–712.
   PubMed Web of Science ®Google Scholar
• Metzler C, Schnabel A, Gross WL, et al. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2008;26:S35–40.
   PubMed Web of Science ®Google Scholar
• Seeliger B, Förster M, Happe J, et al. Interferon-α for induction and maintenance of remission in eosinophilic granulomatosis with polyangiitis: a single-center retrospective observational cohort study. J Rheumatol. 2017;44:806–814.
   PubMed Web of Science ®Google Scholar
• Lee RU, Stevenson DD. Hydroxyurea in the treatment of Churg-Strauss syndrome. J Allergy Clin Immunol. 2009;124:1110–1111.
   PubMed Web of Science ®Google Scholar
• McDermott E, Powell R. Cyclosporin in the treatment of Churg-Strauss syndrome. Ann Rheum Dis. 1998;57:258–259.
   PubMed Web of Science ®Google Scholar
• Assaf C, Mewis G, Orfanos CE, et al. Churg–strauss syndrome: successful treatment with mycophenolate mofetil. Br J Dermatol. 2004;150:598–600.
   PubMed Web of Science ®Google Scholar
• Josselin-Mahr L, Werbrouck-Chiraux A, Garderet L, et al. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase? Rheumatology. 2014;53:378–379.
   PubMed Web of Science ®Google Scholar
• Arbach O, Gross WL, Gause A. Treatment of Refractory Churg-Strauss-Syndrome (CSS) by TNF-a Blockade. Immunobiology. 2002;206:496–501.
   PubMed Web of Science ®Google Scholar
• Beketova TV, Volkov MY, Naryshkin EA, et al. Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report. Clin Rheumatol. 2018;37:1729–1735.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Oppl B, Monach P, et al. Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (churg-strauss). PLoS ONE. 2015;10. DOI:10.1371/journal.pone.0121737.
   PubMed Web of Science ®Google Scholar
• Rhee RL, Holweg CTJ, Wong K, et al. Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. PLoS ONE. 2018;13. DOI:10.1371/journal.pone.0205768.
   Web of Science ®Google Scholar
• Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011;50:215–227.
   PubMed Web of Science ®Google Scholar
• Keating GM. Mepolizumab: first Global Approval. Drugs. 2015;75:2163–2169.
   PubMed Web of Science ®Google Scholar
• Ortega H, Yancey S, Cozens S. Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites. Clin Pharmacol Drug Dev. 2014;3:57–62.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. Am J Respir Crit Care Med. 2007;176:1062–1071.
   PubMed Web of Science ®Google Scholar
• Pouliquen IJ, Kornmann O, Barton SV, et al. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53:1015–1027.
   PubMed Web of Science ®Google Scholar
• Press Announcements. FDA approves Nucala to treat severe asthma. cited 2018 Nov 18. Available from: https://wayback.archive-it.org/7993/20171101170758/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471031.htm
   Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549–556.
   PubMed Web of Science ®Google Scholar
• Plötz S-G, Simon H-U, Darsow U, et al. Use of an Anti–interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334–2339.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Kahn JE, Schwartz LB, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215–1228.
   PubMed Web of Science ®Google Scholar
• Stein ML, Villanueva JM, Buckmeier BK, et al. Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008;121:1473–1483.e4.
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’s role remains uncertain as anti–interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199–204.
   PubMed Web of Science ®Google Scholar
• Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336–1343.
   PubMed Web of Science ®Google Scholar
• Moosig F, Gross WL, Herrmann K, et al. Targeting Interleukin-5 in refractory and relapsing churg–strauss syndrome. Ann Intern Med. 2011;155:341.
   PubMed Web of Science ®Google Scholar
• Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30:S62–5.
   PubMed Web of Science ®Google Scholar
• Steinfeld J, Bradford ES, Brown J. et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. Dec 2018. published online. Doi: 10.1016/j.jaci.2018.11.041
   PubMed Web of Science ®Google Scholar
• Guillevin L. Vasculitis: mepolizumab for eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2017;13:518–519.
   PubMed Web of Science ®Google Scholar
• Wechsler ME Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study. [cited 2018 Nov 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02947945.
   Google Scholar
• Wechsler ME Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study. [cited 2018 Nov 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT03010436.
   Google Scholar
• Markham A. Reslizumab: first Global Approval. Drugs. 2016;76:907–911.
   PubMed Web of Science ®Google Scholar
• Markham A. Benralizumab: first Global Approval. Drugs. 2018;78:505–511.
   PubMed Web of Science ®Google Scholar
• Legrand F, Cao Y, Wechsler J. et al. Siglec-8 in eosinophilic disorders: receptor expression and targeting using chimeric antibodies. J Allergy Clin Immunol. Dec 2018. published online. Doi: 10.1016/j.jaci.2018.10.066
   Web of Science ®Google Scholar
• Legrand F, Tomasevic N, Simakova O, et al. The eosinophil surface receptor epidermal growth factor–like module containing mucin-like hormone receptor 1 (EMR1): A novel therapeutic target for eosinophilic disorders. J Allergy Clin Immunol. 2014;133:1439–1447.e8.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375:2335–2348.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287–2303.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475–2485.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–2496.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 2010;363:221–232.
   PubMed Web of Science ®Google Scholar
• Jones  RB, Tervaert JW, Hauser T, et al. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. N Engl J Med. 2010;363(3):211:–220.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. N Engl J Med. 2014;371:1771–1780.
   PubMed Web of Science ®Google Scholar
• Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:1116–1117.
   PubMed Web of Science ®Google Scholar
• Koukoulaki M, Smith KGC, Jayne DRW. Rituximab in Churg‐Strauss syndrome. Ann Rheum Dis. 2006;65:557–559.
   PubMed Web of Science ®Google Scholar
• Faverio P, Bonaiti G, Bini F, et al. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manag. 2018;14:2385–2396.
   PubMed Web of Science ®Google Scholar
• Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med. 2018;5. DOI:10.3389/fmed.2018.00049.
   Web of Science ®Google Scholar